Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia

Autor:	Ga-Young Song, TaeHyung Kim, Seo-Yeon Ahn, Sung-Hoon Jung, Mihee Kim, Deok-Hwan Yang, Je-Jung Lee, Seung Hyun Choi, Mi Yeon Kim, Chul Won Jung, Jun-Ho Jang, Hee Je Kim, Joon Ho Moon, Sang Kyun Sohn, Jong-Ho Won, Seong-Kyu Park, Sung-Hyun Kim, Zhaolei Zhang, Jae-Sook Ahn, Hyeoung-Joon Kim, Dennis Dong Hwan Kim
Rok vydání:	2022
Předmět:	Transplantation Leukemia Myeloid Acute Recurrence Mutation Hematopoietic Stem Cell Transplantation Humans Hematology Prognosis Disease-Free Survival
Zdroj:	Bone marrow transplantation. 57(12)
ISSN:	1476-5365
Popis:	Secondary-type mutations (STMs), namely SRSF2, SF3B1, U2AF1, ZRSR2, ASXL1, EZH2, BCOR, and STAG2, are more frequently detected in secondary acute myeloid leukemia (AML) than in de novo AML. Whether de novo AML with STMs should be differently managed is, however, unclear. In 394 patients diagnosed with de novo AML who had a normal karyotype, the genetic profiling via targeted deep sequencing of 45 genes revealed 59 patients carrying STMs (STM
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::273777b5b65de113f43bda2a455aa4ae https://pubmed.ncbi.nlm.nih.gov/36151367 Zobrazit plný text záznamu Full text from SpringerLink